Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston
Tumor-localizing properties of bispecific antibody demonstrated by live imaging Lund, Sweden, April 10, 2019 – Alligator Bioscience (Nasdaq ...
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
Lund, Sweden, April 2, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ...
Alligator Bioscience’s Annual Report 2018 published
Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017
Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for th ...
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody Lund, Sweden, March 7, 2019 – Alligator Bioscience (Nasdaq St ...
Alligator Bioscience AB Year-end Report 2018
The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...
Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update
Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report ...
Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies Lund, Sweden, J ...